Prognostic utility of sTREM-1 in predicting early neurological deterioration in patients with acute ischemic stroke treated without reperfusion therapy

• Published in: Journal of stroke and cerebrovascular diseases 2023-11, Vol.32 (11), p.107381-107381, Article 107381
• Main Authors: Fan, Lin, Liu, Ying, Wang, Zhengyang, Mei, Xiaoliang
• Format: Article
• Language: English
• Subjects: Acute ischemic stroke; Early neurological deterioration; Prognostic utility; Serum triggering receptor expressed on myeloid cells type 1
• ISSN: 1052-3057; 1532-8511
• DOI: 10.1016/j.jstrokecerebrovasdis.2023.107381

•High sTREM-1 levels were associated with increased risk of early neurological deterioration.•END is significantly related to the poor prognosis of patients with ischemic stroke.•sTREM-1 lead to the END through the inflammatory reaction and cell damage.•sTREM-1 level is a serum biomarker predicting the possibility of END in AIS patients treated without reperfusion therapy. Serum triggering receptor expressed on myeloid cells type 1 (sTREM-1) is a new type of immunoglobulin superfamily receptor related to inflammation that aggravates brain injury. This study aimed to assess the clinical value of sTREM-1 in predicting early neurological deterioration in patients with acute ischemic stroke (AIS) treated without reperfusion therapy. This prospective cohort study enrolled 315 patients with acute ischemic stroke admitted to the Affiliated Taizhou People's Hospital of Nanjing Medical University between October 2020 and October 2022. The study excluded patients treated with reperfusion therapy. sTREM-1 levels were evaluated within 24 h of the acute ischemic stroke. Early neurological deterioration (END) was defined as an increase in the National Institutes of Health Stroke Scale (NIHSS) score ≥ 4 points within three days after admission. Multivariable analyses were used to investigate the relationship between sTREM-1 levels and END. A total of 81 (25.7 %) patients had early neurological deterioration. Patients in the END group had a higher NIHSS score at admission (P =0.007), CRP levels (P =0.011), white blood cell count (P =0.002), fasting blood glucose levels (P =0.028), and sTREM-1 levels (P